For how we live.
Two WHO-endorsed shots are now available, but a new analysis argues the harder problem is financing them in the lowest-income, highest-burden countries. Nigerian rollout data shows demand outpacing readiness.
In the LATA trial across four countries, 0.9% of teens on long-acting cabotegravir–rilpivirine lost viral suppression by 96 weeks, versus 6.4% on daily tablets — a superiority result.
A survey of 1,042 people in the Syrian city found high prices the leading barrier, and more than half said they knew of deaths they attributed to medication shortages.
ACT-South Asia randomised 1,847 patients in Nepal, Bangladesh and Pakistan. Treatment failed in 5.1% of each group — no benefit from the second antibiotic, and a point in favour of stewardship.
Zoliflodacin is the first antibiotic developed solely for gonorrhoea in decades, and a non-profit holds the rights to register it across most of the world.
The recommendations are conditional, cover three drugs, and come with a projection that fewer than one in ten people who could benefit will have access by 2030.
A TB vaccine financing plan, six target product profiles for children's cancer drugs, and a paediatric research agenda. All three are attempts to specify a product before a market decides to build it.